CA2213660A1 - Aerosol containing beclamethasone nanoparticle dispersions - Google Patents

Aerosol containing beclamethasone nanoparticle dispersions

Info

Publication number
CA2213660A1
CA2213660A1 CA002213660A CA2213660A CA2213660A1 CA 2213660 A1 CA2213660 A1 CA 2213660A1 CA 002213660 A CA002213660 A CA 002213660A CA 2213660 A CA2213660 A CA 2213660A CA 2213660 A1 CA2213660 A1 CA 2213660A1
Authority
CA
Canada
Prior art keywords
beclamethasone
aerosol containing
nanoparticle dispersions
aerosol
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002213660A
Other languages
French (fr)
Other versions
CA2213660C (en
Inventor
Timothy S. Wiedmann
Ray W. Wood
Lan Decastro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Nanosystems L.L.C.
Timothy S. Wiedmann
Ray W. Wood
Lan Decastro
Eastman Kodak Company
Elan Corporation, Plc
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems L.L.C., Timothy S. Wiedmann, Ray W. Wood, Lan Decastro, Eastman Kodak Company, Elan Corporation, Plc, Elan Pharma International Limited filed Critical Nanosystems L.L.C.
Publication of CA2213660A1 publication Critical patent/CA2213660A1/en
Application granted granted Critical
Publication of CA2213660C publication Critical patent/CA2213660C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Abstract

There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble beclomethasone particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment using the aerosol.
CA002213660A 1995-02-24 1996-02-23 Aerosol containing beclamethasone nanoparticle dispersions Expired - Fee Related CA2213660C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/393,973 1995-02-24
US08/393,973 US5747001A (en) 1995-02-24 1995-02-24 Aerosols containing beclomethazone nanoparticle dispersions
PCT/US1996/002347 WO1996025919A1 (en) 1995-02-24 1996-02-23 Aerosols containing beclomethazone nanoparticle dispersions

Publications (2)

Publication Number Publication Date
CA2213660A1 true CA2213660A1 (en) 1996-08-29
CA2213660C CA2213660C (en) 2009-01-20

Family

ID=23557020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002213660A Expired - Fee Related CA2213660C (en) 1995-02-24 1996-02-23 Aerosol containing beclamethasone nanoparticle dispersions

Country Status (9)

Country Link
US (1) US5747001A (en)
EP (2) EP1354583B1 (en)
JP (1) JP4484248B2 (en)
AT (2) ATE250926T1 (en)
AU (1) AU4990796A (en)
CA (1) CA2213660C (en)
DE (2) DE69637288T2 (en)
ES (1) ES2294223T3 (en)
WO (1) WO1996025919A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156706A1 (en) * 2008-06-27 2009-12-30 University Of Strathclyde Pulmonary drug delivery with vesicles comprising non-ionic surfactants

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
UA72189C2 (en) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
DK1150918T3 (en) 1999-02-03 2004-12-20 Biosante Pharmaceuticals Inc Process for the preparation of therapeutic calcium phosphate particles
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
HUP0201457A3 (en) * 1999-12-08 2003-07-28 Pharmacia Corp Chicago Eplerenone crystalline form, pharmaceutical compositions containing them and their preparations
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
BR0008060A (en) * 1999-12-08 2002-02-05 Pharmacia Corp Cyclooxygenase-2 inhibitory compositions having rapid onset of therapeutic efficacy
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
WO2001085136A2 (en) * 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
AR035642A1 (en) * 2000-05-26 2004-06-23 Pharmacia Corp USE OF A CELECOXIB COMPOSITION FOR QUICK PAIN RELIEF
PE20020146A1 (en) * 2000-07-13 2002-03-31 Upjohn Co OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
CA2415789A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002017895A2 (en) * 2000-08-28 2002-03-07 Pharmacia Corporation Use of an aldosterone receptor antagonist to improve cognitive function
US20060177416A1 (en) * 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
AU2001288471B2 (en) 2000-08-31 2006-03-02 Rtp Pharma Inc. Milled particles
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
CA2425035A1 (en) * 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP2005504266A (en) * 2001-06-22 2005-02-10 エラン ファーマ インターナショナル，リミティド High-throughput screening methods using small-scale mills or microfluidics
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
JP2005529060A (en) * 2001-09-25 2005-09-29 ファルマシア コーポレイション Solid form of N- (2-hydroxyacetyl) -5- (4-piperidyl) -4- (4-pyrimidinyl) -3- (4-chlorophenyl) pyrazole
ES2292848T3 (en) * 2001-10-12 2008-03-16 Elan Pharma International Limited COMPOSITIONS THAT HAVE A COMBINATION OF CHARACTERISTICS OF IMMEDIATE RELEASE AND CONTROLLED LIBERATION.
JP2005514393A (en) * 2001-12-19 2005-05-19 ネクター セラピューティクス Supplying aminoglycosides to the lung
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (en) 2002-02-04 2010-07-16 Elan Pharma Int Ltd Nanoparticulate compositions having lysozyme as a surface stabilizer
EP1487419A2 (en) * 2002-03-20 2004-12-22 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
ATE343376T1 (en) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
ES2380318T3 (en) 2002-04-12 2012-05-10 Alkermes Pharma Ireland Limited Megestrol nanoparticular formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
DE60325718D1 (en) * 2002-05-06 2009-02-26 Elan Pharma Int Ltd Nystatin NANOPARTICLE COMPOSITIONS
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (en) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド Nanoparticulate policosanol formulations and novel policosanol combinations
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (en) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド Nanoparticulate topiramate formulation
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
MXPA05009503A (en) * 2003-03-07 2005-10-18 Schering Corp Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia.
US7208486B2 (en) * 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE520935T1 (en) 2003-05-21 2011-09-15 Alexza Pharmaceuticals Inc USE OF A SOLID FUEL LAYER, METHOD FOR PRODUCING SUCH A LAYER AND ASSOCIATED HEATING DEVICE
JP2007501683A (en) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド Sterilization of nanoparticle active substance dispersions by gamma irradiation
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
ATE350024T1 (en) * 2003-10-15 2007-01-15 Pari Gmbh LIQUID PREPARATION CONTAINING TOBRAMYCIN
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
CA2555921A1 (en) * 2004-02-13 2005-09-15 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2586035A1 (en) * 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CN1301747C (en) * 2004-11-30 2007-02-28 深圳市海王英特龙生物技术股份有限公司 Protein medicine microcapsule and inhalational aerosol thereof
UA89513C2 (en) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
CN101132770A (en) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 Nanoparticulate candesartan formulations
CA2597716A1 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
JP2008531721A (en) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド Nanoparticulate compositions of heterocyclic amide derivatives
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
KR20070118258A (en) * 2005-03-16 2007-12-14 엘란 파마 인터내셔널 리미티드 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
MX2007011495A (en) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Nanoparticulate biphosphonate compositions.
EA200702049A1 (en) * 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. COMPOSITIONS OF CORTICOSTEROID NANOPARTICLES WITH ANTIGISTAMINS
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
KR20080007580A (en) 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 Nanoparticulate and controlled release compositions comprising cyclosporine
MX2007012778A (en) * 2005-04-12 2008-01-11 Elan Pharma Int Ltd Nanoparticulate quinazoline derivative formulations.
BRPI0608771A2 (en) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd nanoparticulate clopidogrel formulations
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101262860A (en) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 Nanoparticulate acetaminophen formulations
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
ES2341996T3 (en) * 2005-06-03 2010-06-30 Elan Pharma International Limited IMATINIB MESILATE FORMULATIONS IN THE FORM OF MANOPARTICLES.
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
MX2007015882A (en) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Nanoparticulate clopidogrel and aspirin combination formulations.
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
WO2007008480A1 (en) * 2005-07-07 2007-01-18 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
EP1904041A2 (en) * 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
EP1937217A2 (en) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
JP2009538927A (en) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド Nanoparticulate posaconazole formulation
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
KR20090031618A (en) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 Nanoparticulate formulations of modafinil
CL2007002689A1 (en) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS.
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
CA2715422A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US7828996B1 (en) 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
CN102458380A (en) * 2009-04-24 2012-05-16 先灵公司 Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
FR2945950A1 (en) 2009-05-27 2010-12-03 Elan Pharma Int Ltd ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
AR077692A1 (en) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc SALTS OF 2 - ((R) - (3-CHLOROPHENYL) ((R) -1 - ((S) -2- (METHYLAMINE) -3 - ((R) -TETRAHYDRO-2H-PIRAN-3-IL) PROPILCARBAMOIL ) PIPERIDIN -3-IL) METOXI) METHYL ETILCARBAMATE
US20110236769A1 (en) * 2010-03-23 2011-09-29 Xing Xie Three dimensional electrodes useful for microbial fuel cells
PL2618803T3 (en) * 2010-09-20 2016-08-31 Oreal Aqueous cosmetic composition comprising alkylcellulose
JP6166721B2 (en) 2011-07-22 2017-07-19 ケモセントリックス， インコーポレイテッド 4-tert-Butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt polymorph
ES2625286T3 (en) 2011-07-22 2017-07-19 Chemocentryx, Inc. A crystalline form of the sodium salt of 4-tert-butyl-n- [4-chloro-2- (1-oxy-pyridin-4-carbonyl) -phenyl] -benzenesulfonamide
WO2013030374A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel crystal form
MX2017000134A (en) 2014-06-25 2017-05-01 Glaxosmithkline Ip Dev Ltd Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-( 3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-ca rboxamide.
KR20170047396A (en) 2014-09-08 2017-05-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
CN107709344B (en) 2015-05-01 2022-07-15 共晶制药股份有限公司 Nucleoside analogues for the treatment of flaviviridae and cancer
TWI773641B (en) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 Aqueous suspension containing nano particles of glucocorticoids
WO2017108584A1 (en) 2015-12-21 2017-06-29 L'oreal Composition comprising alkylcellulose, incompatible hydrocarbon and silicone oils and method employing it

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
JPH05963A (en) * 1990-04-13 1993-01-08 Toray Ind Inc Polypeptide composition
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9304585A (en) * 1992-07-31 1994-03-31 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN.
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
CA2091152C (en) * 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
DE4327063A1 (en) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenone particles with modified physicochemical properties
EP0862420A4 (en) * 1995-10-13 1999-11-03 Penn State Res Found Synthesis of drug nanoparticles by spray drying

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156706A1 (en) * 2008-06-27 2009-12-30 University Of Strathclyde Pulmonary drug delivery with vesicles comprising non-ionic surfactants

Also Published As

Publication number Publication date
ATE250926T1 (en) 2003-10-15
DE69637288T2 (en) 2008-07-10
WO1996025919A1 (en) 1996-08-29
EP0810854A4 (en) 1998-09-16
CA2213660C (en) 2009-01-20
ES2294223T3 (en) 2008-04-01
ATE375147T1 (en) 2007-10-15
US5747001A (en) 1998-05-05
EP0810854A1 (en) 1997-12-10
EP1354583A3 (en) 2004-01-07
AU4990796A (en) 1996-09-11
EP0810854B1 (en) 2003-10-01
DE69630207D1 (en) 2003-11-06
JPH11500732A (en) 1999-01-19
JP4484248B2 (en) 2010-06-16
EP1354583A2 (en) 2003-10-22
DE69630207T2 (en) 2004-08-05
EP1354583B1 (en) 2007-10-10
DE69637288D1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
CA2213660A1 (en) Aerosol containing beclamethasone nanoparticle dispersions
CA2213638A1 (en) Aerosols containing nanoparticle dispersions
EP0982378A4 (en) Carbon black and process for producing the same
WO1998029535A3 (en) Nanoscale particles synthesized within an assembled virion
CA2039773A1 (en) Cosmetic composition or aqueous dermo-pharmaceutical containing a suspension of hydrophile lipidic substance hydrated
EP1160018A3 (en) Method and apparatus for fine particle formation
EP1026125A4 (en) Process for producing fine metal oxide particles
EP1197503A3 (en) Process for forming an aqueous polymeric dispersion
GEP20012345B (en) Dispersible Macromolecule Compositions and Methods for Their Preparation and Use
AU665810B2 (en) Process for improving water-whitening resistance of coatings
EP0099179A3 (en) Particulate dispersions
CA2124393A1 (en) Method of making an abrasive compact
CA2253223A1 (en) Titanium dioxide particles
AU4355693A (en) Ultrafine powder for inhalation and production thereof
CA2316312A1 (en) Photocatalytic powder for environmental clarification, said powder-containing polymer composition and shaped article thereof, and processes for producing same
EP0960675A4 (en) Ultrafine particles and process for the production thereof
CA2000960A1 (en) Insecticide
CA2029076A1 (en) Method for treating substrates
CA2327522A1 (en) Incorporation of active substances in carrier matrixes
CA2127581A1 (en) Process for preparing spherules
CA2021534A1 (en) Antiallergic spray preparations
EP1193276A3 (en) Processes for chemically-modifying the surface of emulsion polymer particles
TW369510B (en) Activated carbon and process for producing the same
AU2099000A (en) Method for producing an ultraphobic surface based on nickel hydroxide, ultraphobic surface and the use thereof
AU6916000A (en) Process for producing chemically modified fillers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130225